Drug Trial Radar · NCT00283686
HALT Progression of Polycystic Kidney Disease Study A
Last checked: Nov 19, 2026Latest source record: Apr 21, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
558
Actual
Start
Jan 2006
Primary completion
Jun 2014
Study completion Jun 2014
Sponsor
- Sponsor type
- NIH
- Collaborators
- Boehringer Ingelheim; Merck Sharp & Dohme LLC; Polycystic Kidney Disease Foundation; University of Pittsburgh; Washington University School of Medicine
- First posted
- Jan 30, 2006
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Factorial
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 15 years, up to 64 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The efficacy of interruption of the renin-angiotensin-aldosterone system (RAAS) on the progression of cystic disease and on the decline in renal function in autosomal dominant kidney disease (ADPKD) will be assessed in two multicenter randomized clinical trials targeting different levels of kidney function: 1) early disease defined by GFR \>60 mL/min/1.73 m2 (Study A); and 2) moderately advanced disease defined by GFR 25-60 mL/min/1.73 m2 (Study B; NCT01885559). Participants will be recruited and enrolled, either to Study A or B, over the first three years. Participants enrolled in Study A will be followed for at least 5 years, while those enrolled in Study B will be followed for five-to-eight years, with the average length of follow-up being six and a half years. The two concurrent randomized clinical trials differ by eligibility criteria, interventions and outcomes to be studied.
Conditions
- Kidney, Polycystic
Interventions
LisinoprilDrug
Lisinopril titrated to 5mg, 10mg, 20mg, 40mg
TelmisartanDrug
Telmisartan/Placebo titrated to 40mg and 80mg, as tolerated by participants
PlaceboDrug
Telmisartan/Placebo titrated to 40mg and 80mg, as tolerated by participants
Standard Blood Pressure ControlOther
Achieve standard blood pressure control of 120-130/70-80 mm Hg using step dosing specified in protocol of lisinopril, study drug, hydrochlorothiazide, metoprolol, or non-dihydropyridine and dihydropyridine calcium channel blockers (diltiazem), clonidine, minoxidil, hydralazine at the discretion of the investigator
Low Blood Pressure ControlOther
Achieve low blood pressure control of 95-110/60-75 mm Hg using step dosing specified in protocol of lisinopril, study drug, hydrochlorothiazide, metoprolol, or non-dihydropyridine and dihydropyridine calcium channel blockers (diltiazem), clonidine, minoxidil, hydralazine at the discretion of the investigator
Primary outcomes
What the sponsor says the trial is designed to measure.
- Study A: Percent Annual Change in Total Kidney VolumeTime frame: Baseline and 2-, 4- and 5-year follow-up
Locations
7 sites in 1 country. Site status is shown where the registry gives one.
University of Colorado Health Sciences Center
Aurora, Colorado
Emory University School of Medicine
Atlanta, Georgia
University of Kansas Medical Center
Kansas City, Kansas
Tufts University-New England Medical Center
Boston, Massachusetts
Beth Israel Deaconess Medical Center
Boston, Massachusetts
Mayo Clinic
Rochester, Minnesota
Cleveland Clinic Foundation
Cleveland, Ohio
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.